1. Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G et al (1989) Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 159(4):610-615
2. Sakamaki H, Sato Y, Mori SI, Ohashi K, Tanikawa S, Akiyama H et al (2001) Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation. Int J Hematol 74(3):342-346
3. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D et al (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101(2):407-414
4. Boeckh M, Riddell S, Cunningham T, Myerson D, Flowers M, Bowden R (1996) Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses. Blood 88(Suppl. 1):302a
5. Krause H, Hebart H, Jahn G, Muller CA, Einsele H (1997) Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 19(11):1111-1116